Dianthus Therapeutics, Inc. - Current Ratio

The Current Ratio as of August 2026 (TTM) for Dianthus Therapeutics, Inc. (DNTH) is 26.10

According to Dianthus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 26.10. This represents a change of 21.36% compared to the average of 21.51 of the last 4 quarters.

Dianthus Therapeutics, Inc. (DNTH) Historical Current Ratio (quarterly & annually)

How has DNTH Current Ratio performed in the past?

The mean historical Current Ratio of Dianthus Therapeutics, Inc. over the last ten years is 12.88. The current 26.10 Current Ratio has changed 20.17% with respect to the historical average. Over the past ten years (40 quarters), DNTH's Current Ratio was at its highest in in the March 2024 quarter at 42.52. The Current Ratio was at its lowest in in the March 2017 quarter at 0.

Dianthus Therapeutics, Inc. (DNTH) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Dianthus Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Dianthus Therapeutics, Inc. (DNTH) Average Current Ratio

How has DNTH Current Ratio performed in the past?

The current Current Ratio of Dianthus Therapeutics, Inc. (DNTH) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Dianthus Therapeutics, Inc. (DNTH) Current Ratio vs. Peers

How is DNTH’s Current Ratio compared to its peers?

Dianthus Therapeutics, Inc.’s Current Ratio is less than Enliven Therapeutics, Inc. (40.32), greater than Taysha Gene Therapies, Inc. (14.04), greater than Sana Biotechnology, Inc. (1.29), greater than Atai Beckley Inc. (10.02), greater than Nektar Therapeutics (10.21), greater than AnaptysBio, Inc. (7.58), greater than Oculis Holding AG (5.18), greater than BridgeBio Oncology Therapeutics Inc. (6.16), greater than Immatics N.V. (8.78), greater than Tourmaline Bio, Inc. (24.68),

Build a custom stock screener for Dianthus Therapeutics, Inc. (DNTH) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dianthus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dianthus Therapeutics, Inc. (DNTH) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dianthus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.